Werkgroep Cardiologische centra Nederland

CANTOS (Completed)

A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP
Medicine
canakinumab
Population
ASCVD
Phase
fase III
Starting year
2011
More information
ClinicalTrials.gov